Literature DB >> 3109796

Endocardial fibroelastosis in mucopolysaccharidosis type VI.

L V Fong, S Menahem, J E Wraith, C W Chow.   

Abstract

This case report describes two siblings less than 1 year of age who presented severely ill with a dilated cardiomyopathy. Full blood examination in both cases revealed marked granularity of neutrophils suggestive of mucopolysaccharidosis type VI. There were no physical features of a mucopolysaccharidosis but biochemical evaluation confirmed mucopolysaccharidosis type VI in both children. Autopsy in one patient confirmed endocardial fibroelastosis and electron microscopy of fibroblasts in the myocardium showed distention with membrane-bound vacuoles, consistent with a mucopolysaccharidosis. These siblings developed endocardial fibroelastosis before other clinical manifestations of the mucopolysaccharidosis. Assessment for metabolic causes of a cardiomyopathy is important, as cardiac disease may be the initial manifestation of a metabolic disease.

Entities:  

Mesh:

Year:  1987        PMID: 3109796     DOI: 10.1002/clc.4960100612

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  8 in total

1.  Anesthetic management of a child with Maroteau-Lamy syndrome.

Authors:  M Shiga; K Mikawa; N Maekawa; O Tanaka; R Goto; H Yaku; H Obara
Journal:  J Anesth       Date:  1992-07       Impact factor: 2.078

Review 2.  The mucopolysaccharidoses: a clinical review and guide to management.

Authors:  J E Wraith
Journal:  Arch Dis Child       Date:  1995-03       Impact factor: 3.791

3.  Identification of eleven different mutations including six novel, in the arylsulfatase B gene in Iranian patients with mucopolysaccharidosis type VI.

Authors:  Rokhsareh Jafaryazdi; Sedigheh Shams; Anna Isaian; Aria Setoodeh; Shahram Teimourian
Journal:  Mol Biol Rep       Date:  2019-04-13       Impact factor: 2.316

4.  Electrocardiographic and other cardiac anomalies in beta-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation.

Authors:  A J T Schuldt; T J Hampton; V Chu; C A Vogler; N Galvin; M D Lessard; J E Barker
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-02       Impact factor: 11.205

5.  Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI.

Authors:  Marion M M G Brands; Ingrid M Frohn-Mulder; Marloes L C Hagemans; Wim C J Hop; Esmee Oussoren; Wim A Helbing; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2012-01-26       Impact factor: 4.982

6.  Approach an appropriate decision on fetus with endocardial fibroelastosis in collaboration with cardiovascular profile score: A case report.

Authors:  Hualin Yan; Kaiyu Zhou; Zhang Zhang; Chuan Wang; Nan Guo; Yifei Li; Yimin Hua
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

7.  Combined mucopolysaccharidosis type VI and congenital adrenal hyperplasia in a child: Anesthetic considerations.

Authors:  Abhishek Bansal; Jyotirmoy Das; Raj Kumar; Sangeeta Khanna; Harsh Sapra; Yatin Mehta
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-07

8.  Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.

Authors:  Eugeni Entchev; Ingrid Jantzen; Philippe Masson; Stephanie Bocart; Bruno Bournique; Jean-Michel Luccarini; Andre Bouchot; Olivier Lacombe; Jean-Louis Junien; Pierre Broqua; Mireille Tallandier
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.